Q BioMed Income Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Year	2022	2021	2020	2019	2018	2017 - 2013
Revenue	0.28	0.2	0.03	0	0	Upgrade
Revenue Growth (YoY)	45.38%	551.99%	-	-	-	Upgrade
Cost of Revenue	0.29	0.25	0.33	0.05	0	Upgrade
Gross Profit	-0.01	-0.05	-0.3	-0.05	0	Upgrade
Selling, General & Admin	3.31	6.26	10.97	4.48	5.78	Upgrade
Research & Development	0.13	1.07	1.88	3.54	3.24	Upgrade
Other Operating Expenses	0	0	0	0	0	Upgrade
Operating Expenses	3.44	7.34	12.85	8.02	9.02	Upgrade
Operating Income	-3.45	-7.39	-13.15	-8.02	-9.02	Upgrade
Interest Income	1.38	0.51	0.3	1.46	0	Upgrade
Interest Expense	1.38	0.51	0.3	1.46	0.16	Upgrade
Other Expense / Income	-1.39	0.85	0.35	2.26	-0.16	Upgrade
Pretax Income	-2.05	-8.24	-13.49	-10.28	-9.27	Upgrade
Income Tax	-1.34	0.51	0.3	1.46	0.25	Upgrade
Net Income	-0.72	-8.75	-13.79	-11.74	-9.27	Upgrade
Shares Outstanding (Basic)	45	27	22	15	14	Upgrade
Shares Outstanding (Diluted)	45	27	22	15	14	Upgrade
Shares Change	67.13%	20.84%	47.34%	9.50%	31.23%	Upgrade
EPS (Basic)	-0.02	-0.33	-0.62	-0.78	-0.67	Upgrade
EPS (Diluted)	-0.02	-0.33	-0.62	-0.78	-0.67	Upgrade
Free Cash Flow	1.94	-4.3	-6.23	-4.11	-6.95	Upgrade
Free Cash Flow Per Share	0.04	-0.16	-0.28	-0.27	-0.51	Upgrade
Gross Margin	-3.16%	-26.20%	-986.70%	-	-	Upgrade
Operating Margin	-1211.74%	-3777.44%	-43818.05%	-	-	Upgrade
Profit Margin	-251.83%	-4472.19%	-45961.35%	-	-	Upgrade
Free Cash Flow Margin	682.75%	-2199.44%	-20778.14%	-	-	Upgrade
EBITDA	-0.25	-7.34	-13.1	-7.97	-9.02	Upgrade
EBITDA Margin	-88.77%	-3751.88%	-43651.38%	-	-	Upgrade
Depreciation & Amortization	0.05	0.05	0.05	0.05	0	Upgrade
EBIT	-0.3	-7.39	-13.15	-8.02	-	Upgrade
EBIT Margin	-106.35%	-3777.44%	-43818.05%	-	-	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.